Abstract

RAIMUNDO, Anabela. Tirzepatide: The Beginning of a New Era on Diabetes Treatment. Medicina Interna [online]. 2023, vol.30, n.1, pp.29-37.  Epub Mar 10, 2023. ISSN 0872-671X.  https://doi.org/10.24950/rspmi.1053.

The prevalence of obesity and, consequently, diabetes has been increasing exponentially in recent decades, on a global scale, and this trend is expected to continue in the coming years. Therefore, there is an urgent need for new therapies to help us change this trajectory.

Tirzepatide, the first of a new pharmacological class named co-agonists or dual agonists of the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), has demonstrated in clinical trials published in the last two years, to significantly reduce blood glucose, improve insulin resistance and reduce body weight, with additional benefits on hypertension and lipid profile. Additional data on its impact on cardiovascular endpoints are eagerly awaited.

In this article it is presented a review of this new drug and the new perspectives that its appearance will open, in the future of the treatment of diabetes and obesity.

Keywords : Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Obesity; Tirzepatide..

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )